enavogliflozin
Small moleculeexperimental
Clinical trial activity
32 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
15
Phase 2
10
Phase 3
9
Phase 4
7
Earliest trial started Dec 3, 2017 (NCT03364985)
Timeline
Indications
Approved for
Studied for
- Aortic Valve Stenosis · Phase 4
- Atrial Fibrillation · Phase 4
- Cardiomyopathies · Phase 4
- Cardiomyopathy, Hypertrophic · Phase 4
- Cardiovascular Diseases · Phase 4
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Drug Dosage Calculations · Phase 1
- Endocrine System Diseases · Phase 3
- Glucose Metabolism Disorders · Phase 3
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 4
- Heart Failure, Diastolic · Phase 3
- Kidney Diseases · Phase 4
- Metabolic Diseases · Phase 3
- Obesity · Phase 4
- Tricuspid Valve Insufficiency · Phase 3
Mechanism of action
- Sodium/glucose cotransporter 2INHIBITOR
SLC5A2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
OC[C@H]1O[C@@H](c2cc(Cc3ccc(C4CC4)cc3)c(Cl)c3c2CCO3)[C@H](O)[C@@H](O)[C@@H]1O- Mol. weight
- 446.93 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3703921 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07213310 | Phase 1 | Nov 30, 2025 | Daewoong Pharmaceutical Co. LTD. |
| NCT07240844 | Phase 4 | Nov 24, 2025 | Catholic University of Korea, Sungkyunkwan University |
| NCT06782139 | Phase 4 | Jan 20, 2025 | Daewoong Pharmaceutical Co. LTD., Korea University |
| NCT06644404 | Phase 1 | Oct 26, 2024 | Daewoong Pharmaceutical Co. LTD. |
| NCT06580717 | Phase 4 | Oct 15, 2024 | Keimyung University, Yeungnam University, Yonsei University |
| NCT06606093 | Phase 3 | Sep 23, 2024 | Daewoong Pharmaceutical Co. LTD. |
| NCT06528262 | Phase 4 | Aug 6, 2024 | Yonsei University |
| NCT06399835 | Phase 4 | Feb 1, 2024 | Daewoong Pharmaceutical Co. LTD., Seoul National University |
| NCT06642623 | Phase 4 | Jan 22, 2024 | Yonsei University |
| NCT05672836 | Phase 4 | Dec 31, 2023 | CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD., University of Ulsan |
| NCT06141980 | Phase 3 | Dec 31, 2023 | Daewoong Pharmaceutical Co. LTD., Seoul National University |
| NCT06027307 | Phase 3 | Oct 25, 2023 | Daewoong Pharmaceutical Co. LTD., University of Ulsan |
| NCT05797922 | Phase 1 | Mar 9, 2023 | Chonbuk National University, Daewoong Pharmaceutical Co. LTD. |
| NCT05747664 | Phase 1 | Feb 28, 2023 | Daewoong Pharmaceutical Co. LTD. |
| NCT05737771 | Phase 1 | Jan 25, 2023 | Daewoong Pharmaceutical Co. LTD. |
| NCT05466643 | Phase 3 | Dec 1, 2022 | Daewoong Pharmaceutical Co. LTD. |
| NCT05505994 | Phase 3 | Sep 30, 2022 | Daewoong Pharmaceutical Co. LTD., Peking University |
| NCT05500898 | Phase 1 | Aug 26, 2022 | Daewoong Pharmaceutical Co. LTD. |
| NCT05465668 | Phase 1 | Jul 31, 2022 | Daewoong Pharmaceutical Co. LTD. |
| NCT05192395 | Phase 1 | Apr 15, 2022 | Daewoong Pharmaceutical Co. LTD. |
Showing 20 of 32 trials
Page 1 / 2
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daewoong Pharmaceutical Co. LTD. | For profit | 28 | 24 | 4 | 2017 |
| Yonsei University | Academic/Hospital | 3 | 3 | 1 | 2024 |
| Seoul National University | Academic/Hospital | 2 | 1 | 2 | 2023 |
| University of Ulsan | Academic/Hospital | 2 | 2 | 2 | 2023 |
| CardioVascular Research Foundation, Korea | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Catholic University of Korea | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Chonbuk National University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Keimyung University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Korea University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Sungkyunkwan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Yeungnam University | Academic/Hospital | 1 | 0 | 1 | 2024 |
12 organizations
Page 1 / 1